TLDR Janus kinase inhibitors may help treat lichen planopilaris.
The research letter discusses the treatment of lichen planopilaris (LPP) using Janus kinase (JAK) inhibitors. The authors, Gabriela A. Gonzalez Matheus and Kiarash Khosrotehrani from the Queensland Institute of Dermatology, explore the efficacy of JAK inhibitors in managing this condition. Although no abstract is available, the letter likely reviews existing literature and case studies, such as the use of tofacitinib and baricitinib, which have shown promise in treating LPP. The authors declare no conflicts of interest.
Cited in this study
5 / 5 results
7 citations
,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
48 citations
,
January 2019 in “Journal of dermatological treatment” Women are more likely to have Lichen planopilaris, and treatments with cyclosporine and methotrexate are most effective but less safe than mycophenolate mofetil.
79 citations
,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
27 citations
,
September 2017 in “Archives of Dermatological Research” Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.
160 citations
,
March 2009 in “Seminars in Cutaneous Medicine and Surgery” New insights show Lichen Planopilaris is a rare, scarring hair loss condition, hard to treat, mainly affecting middle-aged women, and significantly impacts mental health.
